Paper
Time-Varying Hazard Patterns and Co-Mutation Profiles of KRAS G12C and G12D in Real-World NSCLC
Authors
Robert Amevor, Dennis Baidoo, Emmanuel Kubuafor
Abstract
Background: KRAS mutations are the largest oncogenic subset in NSCLC. While KRAS G12C is now targetable, no approved therapies exist for G12D. We examined time-to-next-treatment (TTNT) and overall survival (OS) differences between G12C and G12D, allowing for time-varying hazard effects. Methods: De-identified data from AACR Project GENIE BPC NSCLC v2.0-public were analyzed. TTNT served as a real-world surrogate for progression-free survival. Co-mutations (TP53, STK11, KEAP1, SMARCA4, MET), TMB, and PD-L1 were harmonized. Kaplan-Meier, multivariable Cox, and a pre-specified piecewise Cox model (split at median TTNT = 23 months) were applied. Schoenfeld residuals assessed proportional hazards; bootstrap resampling (B=1000) evaluated stability. Results: Among 162 TTNT-evaluable patients (G12C n=130; G12D n=32), median TTNT was 28.6 versus 32.0 months (log-rank p=0.79). Adjusted Cox regression showed no overall hazard difference (HR=0.85; 95% CI 0.53-1.37; p=0.50), but Schoenfeld testing indicated borderline non-proportionality (p=0.053). Piecewise Cox modeling revealed time-varying effects: early TTNT hazard favored G12D (HR=0.41; 95% CI 0.17-0.97; p=0.043) with significant KRAS x period interaction (HR=3.33; p=0.021) and late-period attenuation (HR=1.38; 95% CI 0.77-2.47; p=0.285). Bootstrap resampling confirmed this pattern (median HRearly=0.39; HRlate=1.41). Among 278 OS-evaluable patients (133 deaths), G12D showed improved OS (adjusted HR=0.63; 95% CI 0.39-0.99; p=0.048). G12C tumors exhibited higher TMB (9.79 vs 7.83 mut/Mb; p=0.002) and greater STK11/KEAP1 enrichment. Conclusions: KRAS G12D demonstrated early TTNT advantage and improved OS. Late-period TTNT differences were non-significant (post-hoc power: 12.3%). These exploratory findings require validation in larger cohorts but support allele-specific therapeutic development for G12D.
Metadata
Related papers
Fractal universe and quantum gravity made simple
Fabio Briscese, Gianluca Calcagni • 2026-03-25
POLY-SIM: Polyglot Speaker Identification with Missing Modality Grand Challenge 2026 Evaluation Plan
Marta Moscati, Muhammad Saad Saeed, Marina Zanoni, Mubashir Noman, Rohan Kuma... • 2026-03-25
LensWalk: Agentic Video Understanding by Planning How You See in Videos
Keliang Li, Yansong Li, Hongze Shen, Mengdi Liu, Hong Chang, Shiguang Shan • 2026-03-25
Orientation Reconstruction of Proteins using Coulomb Explosions
Tomas André, Alfredo Bellisario, Nicusor Timneanu, Carl Caleman • 2026-03-25
The role of spatial context and multitask learning in the detection of organic and conventional farming systems based on Sentinel-2 time series
Jan Hemmerling, Marcel Schwieder, Philippe Rufin, Leon-Friedrich Thomas, Mire... • 2026-03-25
Raw Data (Debug)
{
"raw_xml": "<entry>\n <id>http://arxiv.org/abs/2602.19295v1</id>\n <title>Time-Varying Hazard Patterns and Co-Mutation Profiles of KRAS G12C and G12D in Real-World NSCLC</title>\n <updated>2026-02-22T18:07:58Z</updated>\n <link href='https://arxiv.org/abs/2602.19295v1' rel='alternate' type='text/html'/>\n <link href='https://arxiv.org/pdf/2602.19295v1' rel='related' title='pdf' type='application/pdf'/>\n <summary>Background: KRAS mutations are the largest oncogenic subset in NSCLC. While KRAS G12C is now targetable, no approved therapies exist for G12D. We examined time-to-next-treatment (TTNT) and overall survival (OS) differences between G12C and G12D, allowing for time-varying hazard effects. Methods: De-identified data from AACR Project GENIE BPC NSCLC v2.0-public were analyzed. TTNT served as a real-world surrogate for progression-free survival. Co-mutations (TP53, STK11, KEAP1, SMARCA4, MET), TMB, and PD-L1 were harmonized. Kaplan-Meier, multivariable Cox, and a pre-specified piecewise Cox model (split at median TTNT = 23 months) were applied. Schoenfeld residuals assessed proportional hazards; bootstrap resampling (B=1000) evaluated stability. Results: Among 162 TTNT-evaluable patients (G12C n=130; G12D n=32), median TTNT was 28.6 versus 32.0 months (log-rank p=0.79). Adjusted Cox regression showed no overall hazard difference (HR=0.85; 95% CI 0.53-1.37; p=0.50), but Schoenfeld testing indicated borderline non-proportionality (p=0.053). Piecewise Cox modeling revealed time-varying effects: early TTNT hazard favored G12D (HR=0.41; 95% CI 0.17-0.97; p=0.043) with significant KRAS x period interaction (HR=3.33; p=0.021) and late-period attenuation (HR=1.38; 95% CI 0.77-2.47; p=0.285). Bootstrap resampling confirmed this pattern (median HRearly=0.39; HRlate=1.41). Among 278 OS-evaluable patients (133 deaths), G12D showed improved OS (adjusted HR=0.63; 95% CI 0.39-0.99; p=0.048). G12C tumors exhibited higher TMB (9.79 vs 7.83 mut/Mb; p=0.002) and greater STK11/KEAP1 enrichment. Conclusions: KRAS G12D demonstrated early TTNT advantage and improved OS. Late-period TTNT differences were non-significant (post-hoc power: 12.3%). These exploratory findings require validation in larger cohorts but support allele-specific therapeutic development for G12D.</summary>\n <category scheme='http://arxiv.org/schemas/atom' term='q-bio.QM'/>\n <category scheme='http://arxiv.org/schemas/atom' term='stat.AP'/>\n <category scheme='http://arxiv.org/schemas/atom' term='stat.ME'/>\n <published>2026-02-22T18:07:58Z</published>\n <arxiv:primary_category term='q-bio.QM'/>\n <author>\n <name>Robert Amevor</name>\n </author>\n <author>\n <name>Dennis Baidoo</name>\n </author>\n <author>\n <name>Emmanuel Kubuafor</name>\n </author>\n </entry>"
}